Combination of attenuated Salmonella carrying PD‐1 siRNA with nifuroxazide for colon cancer therapy
Colon cancer is a member of malignant tumors in the digestive system. Traditional treatment strategies are ineffective and improving the treatment of colon cancer is an urgent need. Targeting programmed cell death‐1 (PD‐1) by monoclonal antibodies has shown some therapeutic effectiveness and has adv...
Gespeichert in:
| Veröffentlicht in: | Journal of cellular biochemistry 2020-02, Vol.121 (2), p.1973-1985 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1985 |
|---|---|
| container_issue | 2 |
| container_start_page | 1973 |
| container_title | Journal of cellular biochemistry |
| container_volume | 121 |
| creator | Zhao, Tiesuo Feng, Yuchen Guo, Mengmeng Zhang, Chaohui Wu, Qiang Chen, Jian Guo, Sheng Liu, Shenzhen Zhou, Qingsa Wang, Zizhong Fan, Wenyan Zhang, Yongxi Jia, Huijie Feng, Zhiwei |
| description | Colon cancer is a member of malignant tumors in the digestive system. Traditional treatment strategies are ineffective and improving the treatment of colon cancer is an urgent need. Targeting programmed cell death‐1 (PD‐1) by monoclonal antibodies has shown some therapeutic effectiveness and has advantages. Additionally, the Stat3 inhibitor nifuroxazide was employed to promote the antitumor activity. Here, we hypothesized that combining nifuroxazide with PD‐1 small interfering RNA carried by attenuated Salmonella would exert a synergistic antitumor effect on colon cancer. Indeed, treatment with this combination effectively inhibited the development of colon cancer in mice and improved the survival rate. These two novel anticancer agents worked synergistically to elicit potent antitumor immunity and achieve improved therapeutic efficacy. The underlying mechanisms are mainly involved with immune regulation and cell apoptosis. This study provides a previous framework for combining this Stat3 inhibitor with RNAi designed to block immune checkpoint signaling for cancer therapy. |
| doi_str_mv | 10.1002/jcb.29432 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2312548703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2312548703</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-f36b2f793b06780e905cf4026b353c310ec6b33f50950227e38843a41fd7daa03</originalsourceid><addsrcrecordid>eNp1kMtu1DAUQC0EotPCgh9AltjQRdprXyeOl2V4qwLEYx05jk09SuzBTlSGFZ_AN_IleJjCAomVr-Sjo3sPIQ8YnDEAfr4x_RlXAvktsmKgZCUaIW6TFUiEiiPjR-Q45w0AKIX8LjlC1igOgq2IXcep90HPPgYaHdXzbMOiZzvQD3qcYrDjqKnRKe18-EzfPf35_Qej2b9_c0Gv_XxFg3dLil_1Nz9Y6mKiJo5FZXQwNtH5yia93d0jd5wes71_856QT8-ffVy_rC7fvni1vrisDNbIK4dNz51U2EMjW7AKauME8KYv3wYZWFNGdDWoGjiXFttWoBbMDXLQGvCEPD54tyl-WWyeu8lnsz8h2Ljkbt-iFq0ELOijf9BNXFIo2xWKS2xRqqZQpwfKpJhzsq7bJj_ptOsYdPv2XWnf_W5f2Ic3xqWf7PCX_BO7AOcH4NqPdvd_U_d6_eSg_AXX8Yz0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2327383796</pqid></control><display><type>article</type><title>Combination of attenuated Salmonella carrying PD‐1 siRNA with nifuroxazide for colon cancer therapy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zhao, Tiesuo ; Feng, Yuchen ; Guo, Mengmeng ; Zhang, Chaohui ; Wu, Qiang ; Chen, Jian ; Guo, Sheng ; Liu, Shenzhen ; Zhou, Qingsa ; Wang, Zizhong ; Fan, Wenyan ; Zhang, Yongxi ; Jia, Huijie ; Feng, Zhiwei</creator><creatorcontrib>Zhao, Tiesuo ; Feng, Yuchen ; Guo, Mengmeng ; Zhang, Chaohui ; Wu, Qiang ; Chen, Jian ; Guo, Sheng ; Liu, Shenzhen ; Zhou, Qingsa ; Wang, Zizhong ; Fan, Wenyan ; Zhang, Yongxi ; Jia, Huijie ; Feng, Zhiwei</creatorcontrib><description>Colon cancer is a member of malignant tumors in the digestive system. Traditional treatment strategies are ineffective and improving the treatment of colon cancer is an urgent need. Targeting programmed cell death‐1 (PD‐1) by monoclonal antibodies has shown some therapeutic effectiveness and has advantages. Additionally, the Stat3 inhibitor nifuroxazide was employed to promote the antitumor activity. Here, we hypothesized that combining nifuroxazide with PD‐1 small interfering RNA carried by attenuated Salmonella would exert a synergistic antitumor effect on colon cancer. Indeed, treatment with this combination effectively inhibited the development of colon cancer in mice and improved the survival rate. These two novel anticancer agents worked synergistically to elicit potent antitumor immunity and achieve improved therapeutic efficacy. The underlying mechanisms are mainly involved with immune regulation and cell apoptosis. This study provides a previous framework for combining this Stat3 inhibitor with RNAi designed to block immune checkpoint signaling for cancer therapy.</description><identifier>ISSN: 0730-2312</identifier><identifier>EISSN: 1097-4644</identifier><identifier>DOI: 10.1002/jcb.29432</identifier><identifier>PMID: 31692041</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Animals ; Anti-Infective Agents - pharmacology ; Anticancer properties ; Antitumor activity ; Antitumor agents ; Apoptosis ; Cancer ; Cancer therapies ; Cell death ; Cell Movement ; Cell Proliferation ; Colon ; Colon cancer ; Colonic Neoplasms - genetics ; Colonic Neoplasms - metabolism ; Colonic Neoplasms - pathology ; Colonic Neoplasms - therapy ; Colorectal cancer ; combination therapy ; Combined Modality Therapy ; Digestive system ; Female ; Gene expression ; Humans ; Hydroxybenzoates - pharmacology ; Immune checkpoint ; Immunoregulation ; Inhibitors ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Monoclonal antibodies ; nifuroxazide ; Nitrofurans - pharmacology ; PD-1 protein ; PD‐1 ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed Cell Death 1 Receptor - genetics ; RNA, Small Interfering - administration & dosage ; RNA, Small Interfering - genetics ; RNA-mediated interference ; Salmonella ; Salmonella - chemistry ; Salmonella - genetics ; Salmonella - growth & development ; siRNA ; Stat3 protein ; Therapy ; Tumor Cells, Cultured ; Tumors ; Xenograft Model Antitumor Assays</subject><ispartof>Journal of cellular biochemistry, 2020-02, Vol.121 (2), p.1973-1985</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-f36b2f793b06780e905cf4026b353c310ec6b33f50950227e38843a41fd7daa03</citedby><cites>FETCH-LOGICAL-c3532-f36b2f793b06780e905cf4026b353c310ec6b33f50950227e38843a41fd7daa03</cites><orcidid>0000-0002-4267-0198</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcb.29432$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcb.29432$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31692041$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Tiesuo</creatorcontrib><creatorcontrib>Feng, Yuchen</creatorcontrib><creatorcontrib>Guo, Mengmeng</creatorcontrib><creatorcontrib>Zhang, Chaohui</creatorcontrib><creatorcontrib>Wu, Qiang</creatorcontrib><creatorcontrib>Chen, Jian</creatorcontrib><creatorcontrib>Guo, Sheng</creatorcontrib><creatorcontrib>Liu, Shenzhen</creatorcontrib><creatorcontrib>Zhou, Qingsa</creatorcontrib><creatorcontrib>Wang, Zizhong</creatorcontrib><creatorcontrib>Fan, Wenyan</creatorcontrib><creatorcontrib>Zhang, Yongxi</creatorcontrib><creatorcontrib>Jia, Huijie</creatorcontrib><creatorcontrib>Feng, Zhiwei</creatorcontrib><title>Combination of attenuated Salmonella carrying PD‐1 siRNA with nifuroxazide for colon cancer therapy</title><title>Journal of cellular biochemistry</title><addtitle>J Cell Biochem</addtitle><description>Colon cancer is a member of malignant tumors in the digestive system. Traditional treatment strategies are ineffective and improving the treatment of colon cancer is an urgent need. Targeting programmed cell death‐1 (PD‐1) by monoclonal antibodies has shown some therapeutic effectiveness and has advantages. Additionally, the Stat3 inhibitor nifuroxazide was employed to promote the antitumor activity. Here, we hypothesized that combining nifuroxazide with PD‐1 small interfering RNA carried by attenuated Salmonella would exert a synergistic antitumor effect on colon cancer. Indeed, treatment with this combination effectively inhibited the development of colon cancer in mice and improved the survival rate. These two novel anticancer agents worked synergistically to elicit potent antitumor immunity and achieve improved therapeutic efficacy. The underlying mechanisms are mainly involved with immune regulation and cell apoptosis. This study provides a previous framework for combining this Stat3 inhibitor with RNAi designed to block immune checkpoint signaling for cancer therapy.</description><subject>Animals</subject><subject>Anti-Infective Agents - pharmacology</subject><subject>Anticancer properties</subject><subject>Antitumor activity</subject><subject>Antitumor agents</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell death</subject><subject>Cell Movement</subject><subject>Cell Proliferation</subject><subject>Colon</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - genetics</subject><subject>Colonic Neoplasms - metabolism</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonic Neoplasms - therapy</subject><subject>Colorectal cancer</subject><subject>combination therapy</subject><subject>Combined Modality Therapy</subject><subject>Digestive system</subject><subject>Female</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Hydroxybenzoates - pharmacology</subject><subject>Immune checkpoint</subject><subject>Immunoregulation</subject><subject>Inhibitors</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Monoclonal antibodies</subject><subject>nifuroxazide</subject><subject>Nitrofurans - pharmacology</subject><subject>PD-1 protein</subject><subject>PD‐1</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Programmed Cell Death 1 Receptor - genetics</subject><subject>RNA, Small Interfering - administration & dosage</subject><subject>RNA, Small Interfering - genetics</subject><subject>RNA-mediated interference</subject><subject>Salmonella</subject><subject>Salmonella - chemistry</subject><subject>Salmonella - genetics</subject><subject>Salmonella - growth & development</subject><subject>siRNA</subject><subject>Stat3 protein</subject><subject>Therapy</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0730-2312</issn><issn>1097-4644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtu1DAUQC0EotPCgh9AltjQRdprXyeOl2V4qwLEYx05jk09SuzBTlSGFZ_AN_IleJjCAomVr-Sjo3sPIQ8YnDEAfr4x_RlXAvktsmKgZCUaIW6TFUiEiiPjR-Q45w0AKIX8LjlC1igOgq2IXcep90HPPgYaHdXzbMOiZzvQD3qcYrDjqKnRKe18-EzfPf35_Qej2b9_c0Gv_XxFg3dLil_1Nz9Y6mKiJo5FZXQwNtH5yia93d0jd5wes71_856QT8-ffVy_rC7fvni1vrisDNbIK4dNz51U2EMjW7AKauME8KYv3wYZWFNGdDWoGjiXFttWoBbMDXLQGvCEPD54tyl-WWyeu8lnsz8h2Ljkbt-iFq0ELOijf9BNXFIo2xWKS2xRqqZQpwfKpJhzsq7bJj_ptOsYdPv2XWnf_W5f2Ic3xqWf7PCX_BO7AOcH4NqPdvd_U_d6_eSg_AXX8Yz0</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Zhao, Tiesuo</creator><creator>Feng, Yuchen</creator><creator>Guo, Mengmeng</creator><creator>Zhang, Chaohui</creator><creator>Wu, Qiang</creator><creator>Chen, Jian</creator><creator>Guo, Sheng</creator><creator>Liu, Shenzhen</creator><creator>Zhou, Qingsa</creator><creator>Wang, Zizhong</creator><creator>Fan, Wenyan</creator><creator>Zhang, Yongxi</creator><creator>Jia, Huijie</creator><creator>Feng, Zhiwei</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4267-0198</orcidid></search><sort><creationdate>202002</creationdate><title>Combination of attenuated Salmonella carrying PD‐1 siRNA with nifuroxazide for colon cancer therapy</title><author>Zhao, Tiesuo ; Feng, Yuchen ; Guo, Mengmeng ; Zhang, Chaohui ; Wu, Qiang ; Chen, Jian ; Guo, Sheng ; Liu, Shenzhen ; Zhou, Qingsa ; Wang, Zizhong ; Fan, Wenyan ; Zhang, Yongxi ; Jia, Huijie ; Feng, Zhiwei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-f36b2f793b06780e905cf4026b353c310ec6b33f50950227e38843a41fd7daa03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Anti-Infective Agents - pharmacology</topic><topic>Anticancer properties</topic><topic>Antitumor activity</topic><topic>Antitumor agents</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell death</topic><topic>Cell Movement</topic><topic>Cell Proliferation</topic><topic>Colon</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - genetics</topic><topic>Colonic Neoplasms - metabolism</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonic Neoplasms - therapy</topic><topic>Colorectal cancer</topic><topic>combination therapy</topic><topic>Combined Modality Therapy</topic><topic>Digestive system</topic><topic>Female</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Hydroxybenzoates - pharmacology</topic><topic>Immune checkpoint</topic><topic>Immunoregulation</topic><topic>Inhibitors</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Monoclonal antibodies</topic><topic>nifuroxazide</topic><topic>Nitrofurans - pharmacology</topic><topic>PD-1 protein</topic><topic>PD‐1</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Programmed Cell Death 1 Receptor - genetics</topic><topic>RNA, Small Interfering - administration & dosage</topic><topic>RNA, Small Interfering - genetics</topic><topic>RNA-mediated interference</topic><topic>Salmonella</topic><topic>Salmonella - chemistry</topic><topic>Salmonella - genetics</topic><topic>Salmonella - growth & development</topic><topic>siRNA</topic><topic>Stat3 protein</topic><topic>Therapy</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Tiesuo</creatorcontrib><creatorcontrib>Feng, Yuchen</creatorcontrib><creatorcontrib>Guo, Mengmeng</creatorcontrib><creatorcontrib>Zhang, Chaohui</creatorcontrib><creatorcontrib>Wu, Qiang</creatorcontrib><creatorcontrib>Chen, Jian</creatorcontrib><creatorcontrib>Guo, Sheng</creatorcontrib><creatorcontrib>Liu, Shenzhen</creatorcontrib><creatorcontrib>Zhou, Qingsa</creatorcontrib><creatorcontrib>Wang, Zizhong</creatorcontrib><creatorcontrib>Fan, Wenyan</creatorcontrib><creatorcontrib>Zhang, Yongxi</creatorcontrib><creatorcontrib>Jia, Huijie</creatorcontrib><creatorcontrib>Feng, Zhiwei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cellular biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Tiesuo</au><au>Feng, Yuchen</au><au>Guo, Mengmeng</au><au>Zhang, Chaohui</au><au>Wu, Qiang</au><au>Chen, Jian</au><au>Guo, Sheng</au><au>Liu, Shenzhen</au><au>Zhou, Qingsa</au><au>Wang, Zizhong</au><au>Fan, Wenyan</au><au>Zhang, Yongxi</au><au>Jia, Huijie</au><au>Feng, Zhiwei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination of attenuated Salmonella carrying PD‐1 siRNA with nifuroxazide for colon cancer therapy</atitle><jtitle>Journal of cellular biochemistry</jtitle><addtitle>J Cell Biochem</addtitle><date>2020-02</date><risdate>2020</risdate><volume>121</volume><issue>2</issue><spage>1973</spage><epage>1985</epage><pages>1973-1985</pages><issn>0730-2312</issn><eissn>1097-4644</eissn><abstract>Colon cancer is a member of malignant tumors in the digestive system. Traditional treatment strategies are ineffective and improving the treatment of colon cancer is an urgent need. Targeting programmed cell death‐1 (PD‐1) by monoclonal antibodies has shown some therapeutic effectiveness and has advantages. Additionally, the Stat3 inhibitor nifuroxazide was employed to promote the antitumor activity. Here, we hypothesized that combining nifuroxazide with PD‐1 small interfering RNA carried by attenuated Salmonella would exert a synergistic antitumor effect on colon cancer. Indeed, treatment with this combination effectively inhibited the development of colon cancer in mice and improved the survival rate. These two novel anticancer agents worked synergistically to elicit potent antitumor immunity and achieve improved therapeutic efficacy. The underlying mechanisms are mainly involved with immune regulation and cell apoptosis. This study provides a previous framework for combining this Stat3 inhibitor with RNAi designed to block immune checkpoint signaling for cancer therapy.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31692041</pmid><doi>10.1002/jcb.29432</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-4267-0198</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0730-2312 |
| ispartof | Journal of cellular biochemistry, 2020-02, Vol.121 (2), p.1973-1985 |
| issn | 0730-2312 1097-4644 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2312548703 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Anti-Infective Agents - pharmacology Anticancer properties Antitumor activity Antitumor agents Apoptosis Cancer Cancer therapies Cell death Cell Movement Cell Proliferation Colon Colon cancer Colonic Neoplasms - genetics Colonic Neoplasms - metabolism Colonic Neoplasms - pathology Colonic Neoplasms - therapy Colorectal cancer combination therapy Combined Modality Therapy Digestive system Female Gene expression Humans Hydroxybenzoates - pharmacology Immune checkpoint Immunoregulation Inhibitors Mice Mice, Inbred BALB C Mice, Nude Monoclonal antibodies nifuroxazide Nitrofurans - pharmacology PD-1 protein PD‐1 Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - genetics RNA, Small Interfering - administration & dosage RNA, Small Interfering - genetics RNA-mediated interference Salmonella Salmonella - chemistry Salmonella - genetics Salmonella - growth & development siRNA Stat3 protein Therapy Tumor Cells, Cultured Tumors Xenograft Model Antitumor Assays |
| title | Combination of attenuated Salmonella carrying PD‐1 siRNA with nifuroxazide for colon cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A04%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20of%20attenuated%20Salmonella%20carrying%20PD%E2%80%901%20siRNA%20with%20nifuroxazide%20for%20colon%20cancer%20therapy&rft.jtitle=Journal%20of%20cellular%20biochemistry&rft.au=Zhao,%20Tiesuo&rft.date=2020-02&rft.volume=121&rft.issue=2&rft.spage=1973&rft.epage=1985&rft.pages=1973-1985&rft.issn=0730-2312&rft.eissn=1097-4644&rft_id=info:doi/10.1002/jcb.29432&rft_dat=%3Cproquest_cross%3E2312548703%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2327383796&rft_id=info:pmid/31692041&rfr_iscdi=true |